<?xml version='1.0' encoding='utf-8'?>
<document id="25374256"><sentence text="CYP3A4-based drug-drug interaction: CYP3A4 substrates' pharmacokinetic properties and ketoconazole dose regimen effect."><entity charOffset="86-98" id="DDI-PubMed.25374256.s1.e0" text="ketoconazole" /></sentence><sentence text="The aim of the study was to assess the magnitude of the CYP3A4 inhibitory effect of 2 dosing regimens of ketoconazole and the influence of the pharmacokinetic properties of the CYP3A4 substrate on the extent of the substrate exposure increase"><entity charOffset="105-117" id="DDI-PubMed.25374256.s2.e0" text="ketoconazole" /></sentence><sentence text=" For this purpose, a clinical study was conducted and PBPK modeling simulations were performed" /><sentence text=" A crossover study was conducted in healthy subjects" /><sentence text=" The study was designed to compare the effects of different regimens of reversible CYP3A4 inhibitors, i" /><sentence text="e" /><sentence text=", ketoconazole 400 mg OD, ketoconazole 200 mg BID, on two CYP3A4 substrates, alprazolam and midazolam, reflecting different pharmacokinetic properties in terms of first-pass effect and elimination"><entity charOffset="2-14" id="DDI-PubMed.25374256.s7.e0" text="ketoconazole" /><entity charOffset="22-24" id="DDI-PubMed.25374256.s7.e1" text="OD" /><entity charOffset="26-38" id="DDI-PubMed.25374256.s7.e2" text="ketoconazole" /><entity charOffset="77-87" id="DDI-PubMed.25374256.s7.e3" text="alprazolam" /><entity charOffset="92-101" id="DDI-PubMed.25374256.s7.e4" text="midazolam" /><pair ddi="false" e1="DDI-PubMed.25374256.s7.e0" e2="DDI-PubMed.25374256.s7.e0" /><pair ddi="false" e1="DDI-PubMed.25374256.s7.e0" e2="DDI-PubMed.25374256.s7.e1" /><pair ddi="false" e1="DDI-PubMed.25374256.s7.e0" e2="DDI-PubMed.25374256.s7.e2" /><pair ddi="false" e1="DDI-PubMed.25374256.s7.e0" e2="DDI-PubMed.25374256.s7.e3" /><pair ddi="false" e1="DDI-PubMed.25374256.s7.e0" e2="DDI-PubMed.25374256.s7.e4" /><pair ddi="false" e1="DDI-PubMed.25374256.s7.e1" e2="DDI-PubMed.25374256.s7.e1" /><pair ddi="false" e1="DDI-PubMed.25374256.s7.e1" e2="DDI-PubMed.25374256.s7.e2" /><pair ddi="false" e1="DDI-PubMed.25374256.s7.e1" e2="DDI-PubMed.25374256.s7.e3" /><pair ddi="false" e1="DDI-PubMed.25374256.s7.e1" e2="DDI-PubMed.25374256.s7.e4" /><pair ddi="false" e1="DDI-PubMed.25374256.s7.e2" e2="DDI-PubMed.25374256.s7.e2" /><pair ddi="false" e1="DDI-PubMed.25374256.s7.e2" e2="DDI-PubMed.25374256.s7.e3" /><pair ddi="false" e1="DDI-PubMed.25374256.s7.e2" e2="DDI-PubMed.25374256.s7.e4" /><pair ddi="false" e1="DDI-PubMed.25374256.s7.e3" e2="DDI-PubMed.25374256.s7.e3" /><pair ddi="false" e1="DDI-PubMed.25374256.s7.e3" e2="DDI-PubMed.25374256.s7.e4" /></sentence><sentence text=" In parallel, time-based simulations were performed using the Simcyp population-based Simulator to address the usefulness of modeling to assess interaction clinical study design with CYP3A4 substrates" /><sentence text=" Comparison of the OD versus BID regimens for ketoconazole showed an opposite trend for the 2 substrates: BID (200 mg) dosing regimen provided the maximal clearance inhibition for alprazolam, while it was OD (400 mg) dosing regimen for midazolam"><entity charOffset="46-58" id="DDI-PubMed.25374256.s9.e0" text="ketoconazole" /><entity charOffset="180-190" id="DDI-PubMed.25374256.s9.e1" text="alprazolam" /><entity charOffset="19-28" id="DDI-PubMed.25374256.s9.e2" text="OD" /><entity charOffset="205-214" id="DDI-PubMed.25374256.s9.e3" text="OD" /><pair ddi="false" e1="DDI-PubMed.25374256.s9.e2" e2="DDI-PubMed.25374256.s9.e2" /><pair ddi="false" e1="DDI-PubMed.25374256.s9.e2" e2="DDI-PubMed.25374256.s9.e0" /><pair ddi="false" e1="DDI-PubMed.25374256.s9.e2" e2="DDI-PubMed.25374256.s9.e1" /><pair ddi="false" e1="DDI-PubMed.25374256.s9.e2" e2="DDI-PubMed.25374256.s9.e3" /><pair ddi="false" e1="DDI-PubMed.25374256.s9.e0" e2="DDI-PubMed.25374256.s9.e0" /><pair ddi="false" e1="DDI-PubMed.25374256.s9.e0" e2="DDI-PubMed.25374256.s9.e1" /><pair ddi="false" e1="DDI-PubMed.25374256.s9.e0" e2="DDI-PubMed.25374256.s9.e3" /><pair ddi="false" e1="DDI-PubMed.25374256.s9.e1" e2="DDI-PubMed.25374256.s9.e1" /><pair ddi="false" e1="DDI-PubMed.25374256.s9.e1" e2="DDI-PubMed.25374256.s9.e3" /></sentence><sentence text=" However, these effects are moderate despite the well-known pharmacokinetic differences between these substrates, suggesting that these differences are not enough" /><sentence text=" In the other way round, these investigations show how two CYP3A4 substrates can be different without leading to a major impact of the ketoconazole dosing regimen"><entity charOffset="135-147" id="DDI-PubMed.25374256.s11.e0" text="ketoconazole" /></sentence><sentence text=" The clinical findings are consistent with the Simcyp predictions, in particular the opposite trend observed with midazolam and alprazolam and the ketoconazole dosing regimen"><entity charOffset="114-123" id="DDI-PubMed.25374256.s12.e0" text="midazolam" /><entity charOffset="128-138" id="DDI-PubMed.25374256.s12.e1" text="alprazolam" /><entity charOffset="147-159" id="DDI-PubMed.25374256.s12.e2" text="ketoconazole" /><pair ddi="false" e1="DDI-PubMed.25374256.s12.e0" e2="DDI-PubMed.25374256.s12.e0" /><pair ddi="false" e1="DDI-PubMed.25374256.s12.e0" e2="DDI-PubMed.25374256.s12.e1" /><pair ddi="false" e1="DDI-PubMed.25374256.s12.e0" e2="DDI-PubMed.25374256.s12.e2" /><pair ddi="false" e1="DDI-PubMed.25374256.s12.e1" e2="DDI-PubMed.25374256.s12.e1" /><pair ddi="false" e1="DDI-PubMed.25374256.s12.e1" e2="DDI-PubMed.25374256.s12.e2" /></sentence><sentence text=" These clinical investigations showed the influence of the CYP3A4 substrates' pharmacokinetic properties and the relevance of ketoconazole dose regimen on the magnitude of the interaction ratios"><entity charOffset="126-138" id="DDI-PubMed.25374256.s13.e0" text="ketoconazole" /></sentence><sentence text=" In addition, PBPK Simcyp simulations demonstrated how they can be used to help clinical study design assessment to capture the maximum effect" /><sentence text="" /></document>